First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin. - Iacovelli, R.; Ciccarese, C.; Brunelli, M.; Battelli, N.; Buttigliero, C.; Caserta, C.; Buti, S.; Santini, D.; Carella, C.; Galli, L.; Verri, E.; Ermacora, P.; et al. (Annals of Oncology, 2022)